Product Description
The OX40 receptor, also known as CD134, is a tumor necrosis superfamily receptor (TNSFR4) that is recognized as a costimulatory receptor for T cells. OX40 is predominantly expressed on activated CD4 T cells. OX40 has been shown to be essential for the regulation, differentiation, and survival of conventional CD4 and CD8 T cells.1 Multiple studies have demonstrated that activation of the OX40 receptor via ligand or agonist (antibody) binding enhances T cell-mediated antitumor immunity.2-4
Based on its critical co-stimulatory role in T-cell based anti-tumor immunity, OX40 has been identified as a promising therapeutic target in late stage cancers. Additional studies have suggested the utility of combination therapies involving OX40 activation in conjunction with CTLA-4 or PD-1 suppression: enabling the proliferation of T-cells while removing the suppressive action of “immune checkpoint inhibitors”.3,4